The short version
- Why people research itCentral libido and sexual arousal for men and women.
- What the evidence isFDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women, on the RECONNECT phase-3 program.
- What to watchBlood pressure that stays high after hours.
How PT-141 works
Melanocortin MC4R agonist acting in the CNS to drive sexual arousal — works on desire, not just blood flow.
Bremelanotide is the only melanocortin agonist that has been through two phase 3 trials for a behavioral endpoint, and the receptor it works through is the body's satiety receptor. That sentence explains the drug and every complaint about it.
Where it acts. Not on vascular smooth muscle, which is what makes it categorically different from a PDE5 inhibitor. It is a melanocortin receptor agonist acting on hypothalamic neurons, and the circuit has been dissected in mice with unusual precision.
- Injectable
- Nasal
On the goal map: Central desire — melanocortin & dopaminergic (Libido & sexual function)
Research on PT-1416 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA-approved (Vyleesi); human.
Human clinical evidence
FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women, on the RECONNECT phase-3 program. The effect size was statistically significant and modest — a meaningful improvement for a minority rather than a transformation for most.
Nausea was the dominant adverse event, affecting roughly 40% of participants and causing a substantial share of the discontinuations.
Correlative data
Used far beyond the licensed population — men, and women outside the approved indication — where there are no trials. Reported experience is consistent about two things: it works on desire rather than on mechanics.
Flushing and transient blood-pressure rise are frequently reported, matching the trial data.
How the mechanism reads
A melanocortin receptor agonist acting centrally — on MC3R and MC4R in the hypothalamus — not on vascular smooth muscle. That is the key mechanistic distinction from the PDE5 inhibitors: it addresses desire, they address blood flow, and they are not substitutes for each other.
MechanisticMC1R activity is why some users report darkening of moles and freckles, and the shared melanocortin mechanism is why stacking it with Melanotan is predicted to compound that.
Mechanistic
Sources
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology 2019 · PMID 31599840
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection), for subcutaneous use — full prescribing information. DailyMed, U.S. National Library of Medicine
- Semple EA, et al. Melanocortin 4 receptor signaling in Sim1 neurons permits sexual receptivity in female mice. Frontiers in Endocrinology 2023 · PMID 37033219
- Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity and Metabolism 2022 · PMID 35170192
- Parish SJ, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine 2021 · PMID 33814355
- Böhm M, et al. An overview of benefits and risks of chronic melanocortin-1 receptor activation. Journal of the European Academy of Dermatology and Venereology 2024 · PMID 39082868
PT-141 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Uncontrolled high blood pressure or known heart disease: it causes a temporary pressure rise.
- Oral naltrexone use: bremelanotide lowers naltrexone levels.
- Pregnancy or breastfeeding: melanocortin signaling in fetal tissue and milk is unstudied.
- A history of melanoma or a very large number of moles.
- Severe kidney impairment: bremelanotide is cleared by the kidney and exposure rises.
What’s expected
- Sexual desire and arousal rise through central MC4R action rather than blood flow.
- Nausea, often strongest on first use.
- Flushing and a headache.
- A brief blood pressure bump.
Watch for
- Blood pressure that stays high after hours.
- Vomiting that persists while using PT-141.
- New dark patches on gums or skin.
- Chest pain or an erection lasting over four hours.
Labs that tell you it’s working
- Total Testosterone
- Prolactin
- TSH (Thyroid-Stimulating Hormone)
- Comprehensive Metabolic Panel (CMP)
Bremelanotide is a central MC4R agonist for low desire; blood pressure and nausea share that receptor, and hormone labs exclude other causes. PMID 31599840
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
PT-141 FAQ4 common questions
- Is PT-141 approved for human use?
- PT-141 is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is PT-141 researched for?
- Central libido and sexual arousal for men and women.
- Which labs show whether it's doing anything?
- Total Testosterone; Prolactin; TSH; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for PT-141: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





